A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 788



M K B Parmar, J A Ledermann, N Colombo, A du Bois, J-F Delaloye, G B Kristensen, S Wheeler, A M Swart, W Qian, V Torri, I Floriani, G Jayson, A Lamont, C Tropé. Lancet 2003
Times Cited: 792




List of shared articles



Times cited

Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM).
Angiolo Gadducci, Giovanni D Aletti, Fabio Landoni, Roberta Lazzari, Giorgia Mangili, Paola Olivas, Sandro Pignata, Vanda Salutari, Enrico Sartori, Giovanni Scambia,[...]. Tumori 2021
1

The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer.
Katrine Wallace, Kelly Adamski, Ashwini Pai, Darya Rose, Anita Chawla. Pharmacoeconomics 2021
1

Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission.
Oren Smaletz, Gustavo Ismael, Maria Del Pilar Estevez-Diz, Ivana L O Nascimento, Ana Luiza Gomes de Morais, Geraldo Felício Cunha-Junior, Sergio J Azevedo, Venancio A Alves, Ana Maria Moro, Fernanda P Yeda,[...]. Int J Gynecol Cancer 2021
2

The systemic treatment of recurrent ovarian cancer revisited.
T Baert, A Ferrero, J Sehouli, D M O'Donnell, A González-Martín, F Joly, J van der Velden, P Blecharz, D S P Tan, D Querleu,[...]. Ann Oncol 2021
5

Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review.
Melissa Bradbury, Eva Borràs, Assumpció Pérez-Benavente, Antonio Gil-Moreno, Anna Santamaria, Eduard Sabidó. Cancers (Basel) 2021
0

4-step, 2-h carboplatin desensitization in Japanese patients with ovarian cancer: a prospective study.
Meiko Nishimura, Hideki Sakai, Takuma Onoe, Shogen Boku, Takaaki Yokoyama, Genmu Kadokura, Satoshi Morita, Noriyuki Katsumata, Koji Matsumoto. Int J Clin Oncol 2021
1

Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
K E Broekman, M van Kruchten, H van Tinteren, C Sessa, M Jalving, A K L Reyners. ESMO Open 2021
0

Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.
Jonathan S Berek, Malte Renz, Sean Kehoe, Lalit Kumar, Michael Friedlander. Int J Gynaecol Obstet 2021
0

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
J A Ledermann, A C Embleton-Thirsk, T J Perren, G C Jayson, G J S Rustin, S B Kaye, H Hirte, A Oza, M Vaughan, M Friedlander,[...]. ESMO Open 2021
1

A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA.
Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys. Acta Clin Belg 2021
0

The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
Alexander D Murphy, Robert D Morgan, Andrew R Clamp, Gordon C Jayson. Br J Cancer 2021
0

Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Carolyn E Haunschild, Krishnansu S Tewari. Future Oncol 2020
11

Biomarkers that may predict response to immunotherapy in ovarian malignancies.
Curtis D Chin, Charlene M Fares, Gottfried E Konecny, Jianyu Rao. Curr Opin Obstet Gynecol 2020
4

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean,[...]. Lancet Oncol 2020
31

Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?
Joanna Glajzer, Jacek P Grabowski, Jalid Sehouli, Jacobus Pfisterer. Curr Treat Options Oncol 2020
1